Patients with biliary dysfunction, such as primary biliary cholangitis and sclerosing cholangitis, suffer from the inflammation and destruction of bile ducts, thus TFF1-treatment with these patients can overcome their clinical conditions. This evidence concerns the gene TFF1 and biliary liver cirrhosis.